Determination of ED50 and ED95 for adequate sedation of single dose of remazolam in different people

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052360

Enrollment

Unknown

Registered

2021-10-24

Start date

2021-10-30

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anaesthesia

Interventions

Group 1:remimazolam

Group 2:remimazolam

Group 3:remimazolam

Group 4:remimazolam

Eligibility

Sex/Gender

All

Age

19 Years to No maximum

Inclusion criteria

Inclusion criteria: ASA I-III; elective general anesthesia surgery; age greater than 18; obese (BMI>=28) or normal weight (23.9 >=BMI>=18.5); ethical, volunteers were tested voluntarily and signed informed consent.

Exclusion criteria

Exclusion criteria: Those who cannot communicate normally due to deafness, etc.; those with abnormal liver and kidney function; those who are resistant or allergic to benzodiazepines, patients with myasthenia gravis, patients with schizophrenia, and patients with severe depression.

Design outcomes

Primary

Measure	Time frame
depth of the sedtion;	—

Countries

China

Contacts

Public ContactYang Jianjun

the First Affiliated Hospital of Zhengzhou University

18845145049@163.com+86 13357739238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026